The DRB1*15:01-DQB1*06:02 (DR1501-DQ6) haplotype is linked to dominant protection from type 1 diabetes, but the cellular mechanism for this association is unclear. To address this question, we identified multiple DR1501-and DQ6-restricted glutamate decarboxylase 65 (GAD65) and islet-specific glucose-6-phosphatase catalytic subunitrelated protein (IGRP)-specific T cell epitopes. Three of the DR1501/DQ6-restricted epitopes identified were previously reported to be restricted by DRB1*04:01/DRB1*03:01/DQB1*03:02. We also used specific class II tetramer reagents to assess T cell frequencies. Our results indicated that GAD65-and IGRP-specific effector and CD25 + CD127 − FOXP3 + regulatory CD4 + T cells were present at higher frequencies in individuals with the protective haplotype than those with susceptible or neutral haplotypes. We further confirmed higher frequencies of islet antigenspecific effector and regulatory CD4 + T cells in DR1501-DQ6 individuals through a CD154/CD137 up-regulation assay. DR1501-restricted effector T cells were capable of producing interferon- (IFN-) and interleukin-4 (IL-4) but were more likely to produce IL-10 compared with effectors from individuals with susceptible haplotypes. To evaluate their capacity for antigen-specific regulatory activity, we cloned GAD65 and IGRP epitope-specific regulatory T cells. We showed that these regulatory T cells suppressed DR1501-restricted GAD65-and IGRP-specific effectors and DQB1*03:02-restricted GAD65-specific effectors in an antigen-specific fashion. In total, these results suggest that the protective DR1501-DQ6 haplotype confers protection through increased frequencies of islet-specific IL-10producing T effectors and CD25 + CD127 − FOXP3 + regulatory T cells. Increased islet antigenspecific regulatory and effector CD4 + T cells in healthy individuals with the type 1 diabetesprotective haplotype. Sci. Immunol. 5, eaax8767 (2020).
INTRODUCTION
Type 1 diabetes (T1D) is a multifactorial disease in which both genetic and environmental factors contribute to disease development (1) (2) (3) (4) (5) (6) (7) . Genes in the human leukocyte antigen (HLA) region account for up to 50% of the genetic basis of T1D (8) . In particular, both the DRB1*04:01-DQA1*03:01-DQB1*03:02 (DR0401-DQ8) and DRB1*03:01-DQA1*05:01-DQB1*02:01 (DR0301-DQ2) haplotypes are susceptible haplotypes, whereas the DRB1*15:01-DQA1*01:02-DQB1*06:02 (DR1501-DQ6) haplotype confers dominant protection. Other haplotypes such as DRB1*07:01-DQA1*02:01/DQB1*02 (DR0701-DQ2.2) are generally considered to be neutral (1) (2) (3) (8) (9) (10) . For the DR0401-DQ8 haplotype, DQ8 is the most recognized diseasesusceptible allele (11) (12) (13) , but the DR0401 allele also contributes to susceptibility (14, 15) . For the protective DR1501-DQ6 haplotype, the strong linkage disequilibrium between the DR1501 allele and the DQ6 allele renders it difficult to dissect out the relative roles of DR and DQ in conferring protection. However, studies of a family with an unusual DR1501-containing haplotype implicated DQ6 rather than DR1501 as the dominantly protective allele (16) .
The mechanisms by which the disease-susceptible alleles confer risk have been investigated. Disease-associated alleles such as DQ8 and DQ2 have a small noncharged residue at position 57 of the DQB1 chain (located around the pocket 9 region), which shapes the peptide-binding repertories of these DQ molecules (11, 17) . Within the thymus, the threshold of the binding affinity of the T cell receptor (TCR) for peptide-major histocompatibility complex (MHC) will determine whether thymocytes are negatively selected within the thymus or develop into mature T cells and enter the circulation (18) . In addition, thymocytes with TCRs that have affinity near the threshold for negative selection will enter into the periphery as thymusderived regulatory T cells (tT regs ) (19) . It has been proposed that autoreactive thymocytes from hosts with the susceptible HLA alleles are not as efficiently negatively selected and these cells escape into the periphery as autoreactive T cells (20, 21) . tT regs and peripherally induced T regs (pT regs ) (22) counter the activity of these effector T cells (T effs ) and limit autoreactive T cell responses. In individuals with high-risk alleles, additional genetic factors combine with environmental triggers, resulting in the loss of the peripheral regulatory mechanisms, ultimately leading to clinical disease (23) .
Multiple mechanisms have been proposed to explain the dominant protection afforded by protective HLA alleles in T1D. Studies of the nonobese diabetic (NOD) mouse model suggested that protective MHCs are effective in deleting autoreactive T cells (24, 25) . Another mouse model showed that a protective allele could shape the development of intestinal microbiota and prevent insulitis (26) . Studies in human individuals have primarily focused on DQ6 and the epitope stealing hypothesis. Various data have demonstrated that the peptide-binding motif for DQ6 is distinct from the susceptible DQ8 molecules (27, 28) . DQ6 can compete with DQ8 for identical antigenic peptides, and presentation of these peptides by the protective HLA leads to the production of anti-inflammatory cytokines than inflammatory cytokines (28, 29) . Although these results are provocative, the number of studies that have examined the mechanisms by which the DR1501-DQ6 haplotype confers protection in human individuals remains limited.
One area that has not been comprehensively studied is the possible role of DR1501-and DQ6-restricted islet antigen-specific CD4 + T cells in mediating mechanisms of dominant protection. In the present study, we examined islet antigen-specific CD4 + T cells in healthy individuals with the protective DR1501-DQ6 haplotype. To facilitate these assays, we first identified DR1501-and DQ6-restricted T cell epitopes from islet antigens. We then compared the frequencies of islet antigen-specific CD4 + T cells and T regs in healthy individuals with protective haplotype, susceptible haplotypes, or neutral haplotype. We further evaluated the cytokine profiles of islet antigen-specific T effs and the suppressive capacity of DR1501-restricted T regs , allowing us to evaluate multiple pathways that might contribute to the dominant protection provided via the DR1501-DQ6 haplotype.
RESULTS

Increased frequencies of DR1501-restricted GAD65-and IGRP-specific CD4 + T cells in individuals with the protective haplotype
Glutamate decarboxylase 65 (GAD65) and islet-specific glucose-6phosphatase catalytic subunit-related protein (IGRP) are important T1D-associated autoantigens (30, 31) . Previous studies have demonstrated the presence of GAD65-and IGRP-specific autoreactive CD4 + T cells not only in individuals with T1D but also in healthy individuals with DR0401 or DR0301 haplotypes (32) (33) (34) . In this study, we hypothesized that DR1501-and DQ6-restricted CD4 + T cells are likewise present in healthy individuals with the dominant protective haplotype and that these cells have trait that can be measured to reveal an active role in protection. To facilitate our studies, we applied a previously described tetramer-guided epitope mapping (TGEM) approach to identify DR1501-and DQ6-restricted epitopes within GAD65 and IGRP (34, 35) . Through screening experiments with six different DR1501-DQ6-positive healthy individuals, we identified a total of 11 epitopes: 3 DR1501-restricted GAD65, 4 DR1501-restricted IGRP, 3 DQ6-restricted GAD65, and 1 DQ6-restricted IGRP epitopes. The sequences of all these epitopes are summarized in Table 1 . Representative results from a TGEM experiment in identifying DR1501-restricted GAD65 epitopes are shown in fig. S1. Specific tetramer staining results for DR1501-and DQ6-restricted GAD65 and IGRP epitope-specific T cells are shown in fig. S2 . Responses against all of the DR1501-restricted GAD65 and IGRP T cells were detected in more than 50% of the individuals, suggesting that these epitopes were the most immunodominant. A similar approach was applied to identify DR0701-restricted GAD65 and IGRP epitopes. With the exception of the DR0301-restricted GAD65 489-508 epitopes, the DR0401-and DR0301-restricted GAD65 and IGRP epitopes used for assembling tetramers in the current study have been published previously (33, 34, 36) . The sequences of these DR0401-, DR0301-, and DR0701-restricted epitopes are also included in Table 1 , and representative examples of tetramer staining for positive epitopespecific cell lines are shown in fig. S2 .
Specific tetramers were then used to examine the frequencies of GAD65-and IGRP-specific CD4 + T cells directly ex vivo in peripheral blood mononuclear cells (PBMCs) of healthy individuals with either a protective haplotype (DR1501-DQ6), susceptible haplotypes (DR0401-DQ8 or DR0301-DQ2), or a neutral haplotype (DR0701-DQ2.2). For each staining, relevant tetramers corresponding to GAD65 or IGRP epitopes were examined separately. Influenza (Flu) tetramers were also included as a positive control. Examples of these staining experiments are shown in Fig. 1A , and the results for all individuals are summarized in Fig. 1B .
Of particular significance, DR1501-restricted GAD65 T cells had the highest observed frequencies overall. Furthermore, frequencies of DR1501-restricted IGRP-specific CD4 + T cells were higher in DR1501 individuals as compared with IGRP-specific cells in individuals with either high-risk alleles or a neutral allele ( Fig. 1, A and B ). We also discovered that the GAD65 137-156 epitope was the predominant DR1501-restricted epitope because more than 80% of GAD65-specific T cells detected ex vivo exhibited this particular specificity ( fig. S3 ). Additional experiments also showed that GAD65 137-156 was naturally processed and presented, because GAD65 137-156 -specific T cells expanded and could be observed by tetramer staining upon stimulation of PBMCs with GAD65 protein ( fig. S4 ).
High frequencies of GAD65-and IGRP-specific T regs and T effs in individuals with the T1D-protective haplotype
CD4 + T regs are known to be critical for maintaining T cell tolerance and controlling autoimmunity. Multiple studies have shown that human individuals with T1D exhibit defects in the regulatory function of their T regs (37, 38) . Studies in different murine models have shown that boosting T reg number or activity through different approaches can delay or prevent T1D onset (39, 40) . Therefore, clinical trials using polyclonal T regs to treat T1D individuals are currently being pursued (41) . Because individuals with protective HLA alleles exhibited relatively high frequencies of islet antigen-specific CD4 + T cells and yet such individuals are not prone to develop T1D, we hypothesized that islet antigen-specific T regs must be present to mediate protection in these individuals. To address this question, we implemented a staining panel to enumerate T regs . CD4 + CD127 − CD25 + tetramer + cells were designated as islet antigen-specific T regs , because cells with this combination of surface markers have been shown to be highly enriched for forkhead box P3 dependent-positive (FOXP3 + ) T cells ( Fig. 2) (42, 43) . Frequencies of CD4 + CD127 + CD25 − tetramer + T effs were also examined, allowing us to evaluate T reg /T eff ratios. As expected, higher frequencies of DR1501-restricted GAD65/IGRPspecific T regs were observed for individuals in the T1D-protective group than for those in T1D high-risk groups and the neutral-risk DR0701 group (Fig. 3A ). We also observed higher frequencies of DR1501-restricted islet antigen-specific T effs compared with the other groups ( Fig. 3B ). There were no significant differences observed in the T reg /T eff ratios between groups with the exception of GAD65 DR0701 versus GAD65 DR1501 and IGRP DR0301 versus IGRP DR1501 ( Fig. 3C ). Overall, our results suggest that higher frequencies of islet antigen-specific T regs and T effs are present in individuals with the protective DR1501-DQ6 haplotype.
HLA restriction influences the cytokine profiles of islet antigen-specific CD4 + T cells
To characterize possible differences in the cytokine profiles of islet antigen-specific T cells, we single cell-sorted and expanded DR1501restricted GAD65/IGRP tetramer + CD45RA − CD127 − CD25 + T regs and CD45RA − CD127 + CD25 − T effs as T cell clones. The specificity of these clones was validated by tetramer staining. Representative of these efforts, multiple DR1501-restricted GAD65 137-156 and IGRP 225-244 -specific T reg and T eff clones were isolated using this strategy. As expected, tetramer + T reg clones expressed high levels of FOXP3 and Helios, whereas tetramer + T eff clones did not (Fig. 4 , A and B). These data further support the fact that CD45RA − CD127 − CD25 + cells were T regs (44) (45) (46) .
Using the same approach, we also single cell-sorted and expanded DQ6-, DR0401-, and DR0301-restricted GAD65/IGRP tetramer + CD45RA − CD127 + CD25 − T effs of multiple specificities. We then analyzed the cytokine responses of DR1501-restricted GAD65/ IGRP-specific T reg clones and DR1501-, DQ6-, DR0301-, and DR0401-restricted GAD65/IGRP-specific T eff clones elicited by peptide-specific stimulation in vitro. In accord with previous studies (47), DR1501-restricted GAD65/IGRP antigen-specific T reg clones were incapable of producing cytokines such as interleukin-2 (IL-2), IL-4, interferon- (IFN-), IL-17, and IL-21 ( fig. S5 ). A higher percentage of DR1501-restricted GAD65/IGRP antigen-specific T effs produced IL-10 compared with DR-restricted T effs derived from DR0401-DQ8 or DR0301-DQ2 individuals (Fig. 5, A and B) , suggesting that these IL-10-producing DR1501-restricted T effs could contribute to the HLA-linked protection in individuals with the DR1501-DQ6 haplotype. In addition, more DQ6-restricted T effs produced IL-10 compared with DR3-restricted T effs . Although the observed percentage of DQ6-restricted T effs that could produce IL-10 was also higher than DR4-restricted T effs (3.5 versus 2.5%), that difference did not reach statistical significance. In addition, T effs from both the protective haplotype and susceptible haplotypes produced IFN- and IL-4.
Islet antigen-specific T regs suppressed autoreactive T eff responses
In the past, the suppressive capacity of T regs has commonly been assayed upon nonspecific stimulation (e.g., anti-CD3/ CD28 beads) (48, 49) . Because our goal was to evaluate T reg suppression in an antigen-specific fashion, we developed an assay in which the proliferation of islet antigen-specific T effs was examined in the presence of HLA-matched antigenpresenting cells and islet antigen-specific T regs upon specific peptide stimulation. Using this approach, we observed that (i) DR1501-restricted GAD65 137-156specific T regs could inhibit the proliferation of DR1501-restricted GAD65 137-156specific T effs in the presence of the GAD65 137-156 peptide and (ii) DR1501restricted IGRP 225-244 T regs could inhibit the proliferation of IGRP 225-244 -specific T effs in the presence of IGRP 225-244 peptide (Fig. 6, A and B ). Significant suppression was observed with a T reg /T eff ratio of 1:8, demonstrating the potency of antigen-specific T regs . DQ8-restricted islet antigen-specific CD4 + T cells play an important role in the T1D pathogenesis (50) (51) (52) (53) and could be less subject to regulation. We hypothesized that to achieve a dominant protective effect, DR1501-restricted T regs would need to regulate DQ8-restricted T effs in DR1501-DQ6/DR0401-DQ8 heterozygous individuals. To test this hypothesis, we examined the suppressive capacity of DR1501-restricted GAD65 137-156 -specific T regs on DQ8-restricted GAD65 250-266 -specific T effs in the presence of DR1501-DQ6/DR0401-DQ8 antigen-presenting cells and GAD65 137-156 and GAD65 250-266 peptides. As shown in Fig. 7 (A and B), DR1501-restricted GAD65 137-156 T regs inhibited the proliferation of DQ8-restricted GAD65 250-266 T effs in the presence of both GAD65 137-156 and GAD65 250-266 peptides. However, suppression was not observed in the absence of T regs or the GAD65 137-156 peptide.
To investigate the functional mechanism by which islet-specific CD25 + CD127 − T regs exerted their suppressive function, we used transwell experiments to examine whether the suppressive function of these T regs was mediated by cell-to-cell contact or by soluble mediators. Although cell-to-cell contact provided maximum suppressive function, suppression was also observed in the absence of cell-to-cell . The DR0301-restricted tetramer stainings were performed in individuals with DR0301-DQ2 (n = 6). The DR0401-restricted tetramer stainings were performed in individuals with DR0401-DQ8 (n = 10). The DR1501-and DQ6-restricted tetramer stainings were performed in individuals with DR1501-DQ6 (DR1501, n = 14; DQ6, n = 6). Shown is the mean ± SEM. Welch's t test was used. N.S., P ≥ 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001. contact (Fig. 7 , C and D, and fig. S7 ). The cell contact-independent suppressive mechanism was further examined by blocking IL-10. In agreement with our experimental data indicating that the DR1501 T regs did not produce measurable levels of IL-10 ( fig. S5 ), addition of anti-IL-10 antibody did not abrogate the suppressive function ( Fig. 7E and fig. S8 ). In contrast, addition of excess IL-2 partially restored the proliferation of T effs (Fig. 7E and fig. S8 ). These results suggested either that IL-2 consumption by T regs deprived T effs of IL-2 or that addition of IL-2 helps the T effs to overcome the suppressive effect of other unidentified cell contact-dependent or cell contactindependent pathway. In summary, these series of experiments revealed that the DR1501-restricted GAD65-specific T regs used both cell contact-dependent and cell contact-independent mechanisms to suppress T effs .
Increased frequencies of islet antigen-specific T effs and T regs in individuals with protective haplotype by CD154/CD137 up-regulation assay
The results we obtained through these tetramer-based assays were limited to T cells that recognized two T1D-associated autoantigens GAD65 and IGRP. To confirm that comparatively high frequencies of islet antigen-specific T effs and T regs are present in individuals with DR1501-DQ6 haplotype in a more comprehensive fashion, we applied recently developed CD154/CD137 up-regulation assays upon antigen-specific stimulation (47, 54) to identify and enumerate islet antigen-specific T regs and T effs . This approach used overlapping peptides derived from GAD65, IGRP, preproinsulin (PPI), and zinc transporter 8 (ZnT8) as the stimulating antigens. Peptides from PPI and ZnT8 were included because these proteins are considered to be major autoantigens (55) (56) (57) . For these experiments, T effs were defined as CD4 + CD154 + CD69 + T cells, and T regs were defined as CD4 + CD154 − CD137 + GARP + CD127 − CD25 + (Fig. 8A) . Consistent with the results of our tetramer-based experiments, higher frequencies of islet antigen-specific CD4 + T effs and T regs were observed in DR1501-DQ6 individuals compared with DR0401-DQ8 individuals (Fig. 8B ).
DISCUSSION
The mechanism by which the DR1501-DQ6 haplotype confers dominant protection in T1D is unclear. Previous studies have focused on the mechanism of epitope stealing mediated by DQ6. Those studies demonstrated that for individuals with the DR1501-DQ6/DR0401-DQ8 genotype, DQ6 HLA molecules on the surfaces of antigen-presenting cells could compete with DQ8 molecules for identical antigenic peptides and alter DR0401-DQ8-restricted immune responses. In support of this hypothesis, Eerligh et al. (29) demonstrated that the responses of DQ8-restricted insulin-specific T cell clones switched from proinflammatory to anti-inflammatory phenotype when antigen-presenting cells used to generate the clone were switched from a DQ8/8 to a DQ6/8 genotype. Van Lummel et al. (28) showed that binding of insulin B 6-23 to DQ8 was significantly decreased in the presence of DQ6, concluding that the peptide was prevented from binding to DQ8 because it bound preferentially to DQ6. Although our experiments did not directly address whether epitope stealing occurred, this current study did identify multiple DR1501-and DQ6-restricted GAD65 and IGRP epitopes ( Table 1) , three of which overlapped with epitopes that could be presented by DR0401, DR0301, or DQ8. Specifically, the DR1501-and DQ6restricted GAD65 553-572 epitope could be presented by DR0401 (33) , and the DR1501-restricted IGRP 225-244 epitope could be presented by DR0301 (34) . The DQ6-restricted GAD65 241-260 epitope also partially overlapped with a previously reported DQ8-restricted GAD65 250-266 epitope (51, 58) . Thus, the presence of the DR1501 and DQ6 alleles could potentially influence antigen presentation by DR0301, DR0401, and DQ8. However, additional studies will be needed to formally address this question. In addition, cytokines from DR1501-and DQ6-restricted T cell responses should also deviate the immune responses elicited from the susceptible DR-and DQ-restricted T cells. However, the extent of epitope overlap between the protective and susceptible alleles is limited. We reasoned that the DR1501-DQ6 haplotype may have additional protective effects, thereby limiting the risk of developing T1D in individuals who have a susceptible haplotype.
In the current study, we applied both class II tetramer staining and CD154/CD137 up-regulation assays to examine the frequencies of islet antigen-specific CD4 + T cells and T regs in healthy individuals with the protective haplotype, susceptible haplotypes, or a neutral haplotype. We chose to focus on healthy individuals rather than individuals with T1D because we seek to understand the attributes conferred by the HLA, independently of other factors, such as hyperglycemia, that arise as a consequence of T1D onset. On the basis of class II tetramer staining, the frequencies of DR1501-restricted GAD65 autoreactive T effs and T regs in individuals with DR1501-DQ6 haplotype were significantly higher than those of DR0401-, DR0301-, and DR0701-restricted GAD65-specific T effs and T regs in individuals with DR0401-DQ8, DR0301-DQ2, and DR0701-DQ2.2 haplotypes. Frequencies of DR1501-restricted GAD65-specific CD4 + T cells were also found to be higher in comparison with DQ6-restricted GAD65reactive cells. The frequencies of DR1501-restricted IGRP-autoreactive CD4 + and T regs were also significantly higher in most comparison with IGRP-specific cells in DR0401-DQ8, DR0301-DQ2, and DR0701-DQ2.2 individuals. The same relative abundance of islet antigen-specific T effs and T regs in individuals with the protective DR1501-DQ6 haplotype in comparison with individuals with the DR0401-DQ8 haplotype was more comprehensively confirmed using a CD154/CD137 up-regulation assay.
The importance of T regs in T1D is well recognized. For example, it was shown that T regs in T1D individuals are defective in their suppressive capacity (37, 38) . It has also been reported that T effs in T1D are resistant to suppression (59) . Although most studies showed no differences in the frequencies of T regs between healthy and T1D individuals, none of these addressed the frequencies of islet antigen-specific T regs (37, 38, 60, 61) . The difference in frequencies of GAD65 and IGRP T regs among the protective DR1501-DQ6 haplotype group and the susceptible and neutral HLA haplotype groups appears to be islet antigen specific, because there was no difference in the overall percentage of CD25 + CD127 − T regs in the total CD4 + T cell populations and the frequencies of Flu B hemagglutinin (HA)-specific T regs between these different groups were similar ( fig. S6, A and B) . This supports a possible role of islet antigen-specific T reg in mediating the protective effect in individuals with the DR1501-DQ6 haplotype and implies that the protective effect is both antigen and HLA specific. Through our methodology, we also highlighted the successful cloning of naturally derived epitope-specific T regs from human individuals. In this study, the T reg epitopes studied were identical to T eff epitopes. Because the isolation of these T regs was biased by the use of tetramer reagents, it remains unclear whether epitopes recognized by T regs and T effs are essentially identical. It also remains unclear whether the T regs detected in our assays are pT regs or tT regs . However, the T reg clones isolated were Helios + , raising the possibility that they could be thymically derived (62) . It will also be of interest to compare the suppression potency of antigen-specific T regs isolated from healthy individuals with protective and susceptible alleles as well as from T1D individuals.
The presence of higher frequencies of epitope-specific T regs in an individual with a protective haplotype was also reported for Goodpasture disease (63) . In that study, individuals with a protective haplotype had higher frequencies of T regs and lower frequencies of T effs compared with individuals with susceptible haplotype, leading to clones (specificities of these clones are shown in table S1) and 16 T reg clones (specificities of these clones are shown in table S2) generated from at least six independent experiments. Shown is the mean ± SEM. Welch's t test was used. ****P < 0.0001. significant differences in the T reg /T eff ratio between the two groups. In our current study, we also observed a higher frequency of T effs in individuals with a protective haplotype compared with those with susceptible haplotypes, leading to similar T reg /T eff ratios between the protective and susceptible groups.
The high frequency of autoreactive T effs in DR1501-DQ6 individuals is in contrast to the conventional reasoning that the frequency of CD4 + autoreactive T cells is higher in individuals with the susceptible haplotypes. However, we also observed that a higher percentage of T cells derived from DR1501-restricted autoreactive T effs produced IL-10 compared with the DR0401-and DR0301-restricted cells. The propensity of the DR1501-restricted cells to produce IL-10 could be taken to suggest deviation toward a Tr1-like lineage or a reduced potential for sustaining autoreactivity. In total, our data suggest that protection mediated through the DR1501-DQ6 haplotype is not due to the absence of autoreactive T effs . Rather, the high abundance of DR1501-restricted islet-specific T regs and the altered cytokine profiles of islet-specific T effs imply a multifaceted role of these cells in conferring dominant protection.
Hauben et al. (64) have put forth a hypothesis of "beneficial autoimmunity," in which robust but adequately regulated autoreactive T cell responses can facilitate the clearance of damaged tissues and prevent the subsequent self-perpetuating inflammation and autoimmunity. In this model, cytokines and chemokines from autoreactive T cells will activate the innate immune cells for clearance of dead cells, which would be a source of autoantigens that propagate the inflammatory and autoimmune responses. In contrast, a weak initial CD4 + T cell response, which is unable to activate the innate immune cells to clear the damaged tissues, will potentially lead to chronic inflammation and autoimmunity.
The observation of high frequencies of islet-specific T effs and T regs in the protective group supports this beneficial autoimmunity model. In this hypothetical scenario,  cell injury will lead to trafficking of DR1501-restricted autoreactive T cells into the injured tissue site. Cytokines/chemokines from the DR1501-restricted T effs then activate the innate cells that promote the clearance of  cell debris as a first step to restore immune homeostasis. At the same time, activation of DR1501-restricted islet antigen-specific T regs and production of IL-10 from DR1501-restricted T effs will act together to down-regulate the DR1501-restricted T eff responses and the innate responses from becoming overexuberant and harmful to the host. In addition, both FOXP3 + T regs and IL-10 from T effs are capable of regulating other islet antigen-specific T cells restricted by other class I and class II alleles, including DQ8-restricted autoreactive T cells, in their immediate environment. Hence, a high frequency of T effs that can be adequately restrained by T regs could be beneficial to the host in tissue healing.
Our study demonstrates that the DR1501-DQ6 haplotype appears to confer protection through multiple pathways. First, DR1501restricted islet-specific FOXP3 + T regs and IL-10-producing Tr1-like cells can down-modulate the pathogenic immune responses, beneficially altering the islet milieu. There is also the possibility that IFN- production from DR1501-restricted T effs can provide beneficial autoimmunity, facilitating the elimination of autoantigens through clearance of damaged islets in an indirect fashion. In total, these data show that individuals with the DR1501-DQ6 haplotype have unique T cell repertories that can act through different mechanisms to achieve dominant protection. Additional studies in examining autoreactive T cells restricted by additional susceptible, neutral, and protective DR and DQ alleles should be fruitful in dissecting the cellular pathways that promote disease protection.
MATERIALS AND METHODS
Study design
The goal of this study was to determine the role of DR1501-DQ6restricted islet antigen-specific CD4 + T cells in conferring dominant protection in T1D. DR1501-and DQ6-restricted GAD65-and IGRP-specific CD4 + T cell epitopes were identified by TGEM. Frequencies of islet antigen-specific T effs and T regs in healthy individuals with DR1501-DQ6, DR0401-DQ8, DR0301-DQ2, and DR0701-DQ2.2 haplotypes were analyzed by ex vivo staining with class II tetramers. GAD65-and IGRP-specific CD4 + T cells from individuals with different haplotypes were cloned, and their cytokine profiles were examined. The suppressive function of DR1501-restricted T reg clones was examined by an in vitro suppression assay in an antigenspecific fashion. Besides GAD65 and IGRP, other islet antigens including PPI and ZnT8 peptide pools were included in CD154/ CD137 assays to comprehensively identify the islet antigen-specific CD4 + T effs and T regs in individuals with the DR1501-DQ6 or DR0401-DQ8 haplotype.
Individuals
Healthy individuals with specific HLA class II haplotypes of interest were recruited at Benaroya Research Institute at Virginia Mason under a study approved by the Benaroya Research Institute Institutional Review Board. All individuals were recruited with written informed consent. A total of 16 DR1501-DQ6 individuals were included in this study. Participants who did not have DR1501-DQ6 but had other HLA haplotypes of interest, including 10 with DR0401-DQ8, 6 with DR0301-DQ2, and 7 with DR0701-DQ2.2, were also recruited to this study.
Peptides and tetramers
The islet antigens in our study included GAD65, IGRP, PPI, and ZnT8 proteins. Overlapping peptides that were 20 amino acids in length with 12-amino acid overlap that covered the entire protein for each of the four antigens mentioned were ordered from Mimotopes. Peptides were loaded onto the specific HLA class II protein to generate tetramers as previously described (35, 65) .
Tetramer-guided epitope mapping TGEM was performed as described (34, 35) to identify MHC class II-restricted peptide epitopes for the islet antigens GAD65 and IGRP. Briefly, GAD65-and IGRP-derived peptides were divided into pools of five peptides each. Each pool was added to an individual well in a 24-well plate, with 4 × 10 6 to 5 × 10 6 PBMCs isolated from a donor of interest. Cells were cultured for 14 to 19 days and then stained with pooled peptide-loaded tetramers. Cells from wells with a positive staining result were screened again by staining with each tetramer loaded with individual peptides that belong to that particular peptide pool. The specific peptide for the loaded tetramer that gave a positive staining was considered to be an epitope. The specificity of tetramer staining was confirmed by single-cell cloning of the tetramer-positive cells and then restaining the T cell clone with the tetramer used for sorting.
Ex vivo peptide-MHC II tetramer analysis
PBMCs were isolated from whole-blood samples by Ficoll underlay. Ex vivo tetramer staining was then performed as described previously (51, 66) . Briefly, 90 million PBMCs were treated with dasatinib (50 nM) at 37°C for 5 min, washed once, and then divided into three tubes. Cells were then were stained with phycoerythrin (PE)-, PE-Cy5-, or PE-Dazzle 594-labeled tetramers (20 g/ml for each tetramer) at room temperature for 1.5 to 2 hours. The tetramers used were selected to match the relevant HLA of interest as listed in Table 1 . Cells were then washed and incubated with anti-PE Micro-Beads (Miltenyi Biotec) at 4°C for 10 min. After reserving a precolumn fraction (used to estimate the total number of CD4 + T cells within the sample), tetramer-positive cells were enriched using MS column (Miltenyi Biotec) and then stained with other surface antibodies including anti-CXCR5-allophycocyanin (APC)-Cy7 (clone J252D4), anti-CCR4-PerCP-Cy5.5 (clone L291H4), anti-CXCR3-BUV395 (clone 1C6/CXCR3, BD Biosciences), anti-CCR6-BV650 (clone G034E3), anti-CD45RA-AF700 (clone HI100), anti-CD4-BUV737(clone SK3, BD Biosciences), anti-CD127-BV711 (clone A019D5), and anti-CD25-BV785 (clone M-A251), and a dump channel consisting of anti-CD14-BV510 (clone M5E2), anti-CD19-BV510 (clone SJ25C1), anti-CD56-BV510 (clone HCD56), and Fixable Viability Stain 510 (BD Biosciences). These surface-stained cells were treated with Nuclear Transcription Factor Buffer Set and then intracellularly stained with anti-FOXP3-FITC (fluorescein isothiocyanate) (clone 206D) and anti-Helios-APC (clone 22F6) as necessary. All reagents mentioned above were purchased from BioLegend except otherwise noted. Cells in all three tubes were then pooled together and analyzed with a BD LSRII; data collected were analyzed by FlowJo 10.4.2. Frequencies were calculated by dividing the number of tetramer-positive cells in the bound fraction by the number of total CD4 + T cells, as determined by analyzing the precolumn sample.
Single-cell cloning of peptide-MHC II tetramer-positive cells
Antigen-specific CD4 + T cells were magnetically enriched as described above and then single cell-sorted by BD FACSAria Fusion. Individual dump gate negative CD4 + CD45RA − tetramer + cells were sorted at single-cell purity directly into individual wells of a 96-well plate and then expanded with 0.1 million irradiated human PBMCs as feeder cells and phytohemagglutinin (PHA) (1 g/ml; Remel) in 100 l of T cell medium (TCM; consisting of RPMI with 10% pooled human serum and 1% sodium pyruvate, glutamine, and penicillin/streptomycin; Invitrogen) per well as described (67) . Recombinant human IL-2 (PeproTech) was added to the culture the next day to reach the final concentration of 300 IU/ml (41) for CD127 − CD25 + CD4 + T regs or 10 IU/ml for CD127 + CD25 − CD4 + T effs . The cells were incubated at 37°C, 5% CO 2 for 2 to 3 weeks and fed with fresh TCM and IL-2 as necessary. After in vitro expansion, the antigen specificity of T cell clones was confirmed again by tetramer staining.
Cytokine assay
After stimulation and expansion, T cell clones were rested in TCM without PHA or IL-2 for 3 days. For each well, about 0.1 million cells in 100 l of TCM were cultured with phorbol 12-myristate 13acetate and ionomycin (T Cell Activation Cocktail, BioLegend), antigen-specific peptide (10 g/ml; Mimotopes), or irrelevant peptide (10 g/ml; influenza matrix protein MP 97-116, Mimotopes; see Table 1 ) as a negative control. Cells were stimulated for 6 hours and treated with brefeldin A (5.0 g/ml) for the last 3 hours. Cell surface staining was performed first, followed by fixation, permeabilization, and then staining of intracellular cytokines including IL-2-BV650 (clone MQ1-17H12), IL-4-BV605 (clone MP4-25D2), IL-10-PE-Cy7 (clone JES3-9D7), IFN--BV421 (clone 4S.B3), IL-21-APC (clone 3A3-N2), and IL-17A-PE (clone BL168). All reagents mentioned above were purchased from BioLegend.
T reg in vitro suppression assay
The regulatory function of the antigen-specific T reg clones was examined in an antigen-specific fashion by using a suppression assay that was adapted from a previously described assay (48, 49) . Briefly, 10,000 cells of the islet antigen-specific T eff clone of interest were used as responder cells and labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE) or using the CellTrace Violet Cell Proliferation Kit (Invitrogen). The responder cells were cultured with T regs at T reg /T eff ratios of 0:1, 1:8, and 1:1. HLA-matched PBMCs (100,000) were pulsed with specific antigenic peptide at 10 g/ml, irradiated at 50 Gy, and used as antigen-presenting cells. In some experiments, anti-IL-10 antibody (10 g/ml, clone JES3-19F1, BD Biosciences), its isotype control (clone R35-95, BD Biosciences), or human IL-2 (20 IU/ml, Roche) was added. After antigen-specific stimulation for 6 days, the proliferation of responder cells was analyzed with an LSRII flow cytometer (BD Biosciences). The percentage of suppression was calculated by using the following formula: % Suppression = (proliferation of responder cell cultured alone − proliferation of responder cell cocultured with T regs )/proliferation of responder cell cultured alone. For transwell experiments, Millicell-96 cell culture insert plates (Millipore) were used. Ten thousand CFSE-labeled DQ8-restricted GAD65-specific T effs and 100,000 irradiated PBMCs from a DR1501/DR4-DQ8 individual were placed in both the upper and lower chambers. DR1501-restricted GAD65-specific T regs were added to the upper chamber only at different T reg /T eff ratios. Both T effs and T regs were stimulated with relevant peptides (10 g/ml). After 6 days of culture, proliferation of T effs in both upper and lower chambers was analyzed in parallel to show the effect of cell-cell contact on T reg suppression.
CD154/CD137 assays for detection of islet-specific T effs and T regs
Assays for the detection of islet-specific CD4 + T effs and T regs were performed essentially as described (47, 54, 67) . Briefly, 30 million PBMCs in 2 ml of TCM were stimulated for 16 hours with T1D peptide pools (2 g/ml for each peptide) derived from GAD65, IGRP, PPI, and ZnT8 proteins in the presence of anti-CD40 (1 g/ml, clone HB-14, Miltenyi Biotec). Cells were then stained with PEconjugated anti-CD154 (clone 5C8, Miltenyi Biotec) and PE-Cy7conjugated anti-CD137 (clone 4B4-1). A 1 / 10 th fraction of the cells was saved, and the rest of the CD154-PE + /CD137-PE-Cy7 + cells were magnetically enriched by anti-PE MicroBeads and MS column (Miltenyi Biotec). The enriched cells were stained with additional surface antibodies including anti-CD69-PE-Cy5 (clone FN50), anti-GARP-APC (clone 7B11), anti-CD45RA-AF700 (clone HI100), anti-CD4-BUV737 (clone SK3, BD Biosciences), anti-CD127-BV711 (clone A019D5), and anti-CD25-BV785 (clone M-A251), and a dump channel consisting of anti-CD14-BV510 (clone M5E2), anti-CD19-BV510 (clone SJ25C1), anti-CD56-BV510 (clone HCD56), and Fixable Viability Stain 510 (BD Biosciences). All antibodies mentioned above were purchased from BioLegend except otherwise noted. The frequency of T effs was calculated by using the formula F = n/N, where n designates the number of CD154 + CD69 + cells in the bound fraction after enrichment and N is the total number of CD4 + T cells, which was calculated as 10 × the number of unenriched cell. The frequency of T regs was calculated by using the same formula, where n is designated as the number of CD154 − CD137 + GARP + CD127 − CD25 + CD4 + T cells.
Statistical analysis
GraphPad Prism software (version 7.05) was used for data analysis. Value is the mean ± SEM (for population) or SD (for T reg in vitro suppression assay). Welch's t test or paired t test was used. N.S., P ≥ 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001. Outliers were identified by ROUT (robust regression and outlier removal; Q = 1%) and then removed to prevent outlier bias.
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